11 August 2026 $250,000 in Funding Received under Financing Facility Argent BioPharma Ltd ( ASX: RGT ) ( Argent or the Company ) confirms that it has received A$250,000 in funding under the A$11 million convertible securities financing agreement with C/M Capital Master Fund, LP and...
$250,000 in Funding Received under Financing Facility
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Argent Biopharma
- US Veterinary Development Programme for CannEpil Commences
- Notification of cessation of securities - RGT
- CannEpil Global Licence Expands into Veterinary Healthcare
- Quarterly Activities/Appendix 4C Cash Flow Report
- RGT Executes Global CannEpil Licensing Deal for US$5.5M
Later from Argent Biopharma
- Proposed issue of securities - RGT
- FDA-CVM Establish INAD File for CannEpil Veterinary Program
- Appendix 4G and Corporate Governance Statement
- Appendix 4E and 2026 Annual Report
- Argent Signs NLC Licence to Expand Antiviral Portfolio
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma